drugset
drugset / Trial / NCT04557163

Drug-drug Interaction Study with TS-142 in Healthy Adult Subjects (concomitant Administration of Itraconazole)

NCT04557163 ↗

Phase 1 Completed 10 enrolled Taisho Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, single-center, single-sequence study to evaluate the concomitant effects of the potent CYP3A inhibitor itraconazole on the single-dose pharmakokinetics, safety and tolerability of oral TS-142 in healthy subjects.

Timeline

Start
2020-10-13
Primary completion
2020-11-14
Completion
2020-11-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 200 mg Oral
Subject TS-142 Small molecule 1 mg Oral
Subject TS-142 Small molecule 5 mg Oral

Indications

No indication recorded.